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A person with symptoms and signs suggestive of tuberculosis and 
found to have the disease (through investigations or clinically). 
Eligibility  A person who meets the criteria to be offered Isoniazid 
Preventive Therapy. 
Gene Expert  A WHO-approved cartridge-based rapid diagnostic test that uses 
a molecular technique to simultaneous detect Mycobacterium 




The administration of a medicine called Isoniazid to individuals 
with a latent infection of Mycobacterium tuberculosis to prevent 
progression to active TB disease.  
People Living with 
HIV  
Children, Adolescents and Adults infected with the HIV virus in 
their body. 
IPT Uptake The proportion of PLHIV on ART care and eligible for IPT who 
had been initiated on INH treatment. 
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active Tuberculosis. 
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refill 
Regularity of INH refills for the cases enrolled on IPT. 
IPT default Patients not taking INH for two months or more, consecutively 
after starting treatment. 
Pre IPT counseling Patient education sessions about IPT that take place before 
initiation of the course of treatment. 


















Background: Tuberculosis (TB) remains a major public health problem worldwide, 
especially in developing countries. Despite clear evidence that isoniazid preventive therapy 
(IPT) can reduce the risk of TB disease among PLHIV, uptake of IPT is low in many 
resource-limited settings with high TB-burden. Therefore, this study was carried out to 
determine the level of IPT uptake and its associated factors amongst PLHIV who do not 
have active TB disease. 
Methodology: This was a retrospective quantitative study amongst newly diagnosed 
PLHIV who do not have active TB in the FY 2019/20 and enrolled for ART in HIV/TB 
Clinics in Butebo district in Uganda. Demographic factors (age, sex, religion, marital status, 
employment status, education level, area of residence, household density), health facility 
factors (pre-IPT counselling), community factors (distance from H/C, incurred costs to 
reach H/C), and IPT drug related factors (IPT adherence, default on IPT, frequency of INH 
refill, INH stockouts) data were collected from 4 selected health facilities using 
questionnaire tool. Descriptive statistics was used to generate frequency cross tables.  
Results: A total of 272 eligible cases were included in the study amongst which 93 
(34.2%) achieved IPT uptake. Mean duration (years) between HIV diagnosis and start of 
IPT was 4.31 (SD ±3.782). IPT Uptake among males 34 (37%) and females 59 (32.8%). 
Modal age group for IPT Uptakes was 20-35 years. 7 (70%) of the employed took up IPT 
compared to 86 (32.8%) of the employed. IPT uptake was highest among the married 62 




Other factors which affected the rate of IPT Uptake include Education level, residence 
status, household density, Incurrence of costs to reach H/C, Distance from H/C, and Pre-
IPT counselling. IPT completion was 91 (97.8%). All cases with good adherence to IPT 
adherence completed treatment 84 (100%) compared to 7 (77.8%) among those with poor 
adherence. Of the cases who defaulted on IPT 4 (66.7%) completed IPT while 87 (100%) 
of those who did not default completed. All the cases 88 (100%) who had regular INH 
refill completed IPT compared to 3 (60%) with irregular refill. 91 (97.8%) did not 
experience INH stock outs and completed IPT.    
Conclusion: This study showed that IPT Uptake was very low at 34.2%. IPT uptake may 
be scaled up by addressing the factors affecting IPT Uptake, as well as integrating IPT 
services in routine HIV care, enhancing supervision and monitoring, simplifying screening 
procedures, providing free screening, training of health workers, and improving logistical 
supplies at the health centers. The shortcomings need to be discussed at all levels of 
management from the Health Center, the District and centrally at the Ministry of Health 







  INTRODUCTION 
1.1 Background 
Tuberculosis is a preventable and curable infectious disease caused by Mycobacterium 
Tuberculosis.1 It is one of the leading ten causes of morbidity and mortality throughout the 
world.2 In 2019, 10 million people acquired TB globally. Africa accounts for 24.5% of 
global TB burden with over 1.4 million cases notified, and 608,000 died from the disease. 
Mortality from Human Immunodeficiency Virus/TB coinfection was over 211,000 in 2019. 
Additionally, the percentage of People Living with HIV who were newly enrolled on 
Isoniazid Preventive Therapy was 60%.3 
 IPT reduces incidence of TB by up to 60% reduces mortality among PLHIV by 55%. The 
World Health Organization recommends the use of Isoniazid given daily for 6 months. 
PLHIV who do not have active TB are recommended to take IPT.4 
According to a United States Centers for Disease Control and Prevention report, HIV 
prevalence in Uganda was 5.7% and the burden of TB was at 201 per 100,000 people as of 
2017. 40% of PLHIV were co-infected with TB.5 In 2014, Uganda’s Ministry of Health 
instituted Policy guidelines for health workers indicating that all PLHIV must be screened 
and have IPT given to all those without active TB.6 The WHO target for IPT coverage is ≥ 
90% by 2035.7 In one Kenyan study conducted in 2003 to 2012, only 0.5% of newly 
diagnosed PLHIV were initiated on TB preventive treatment in Uganda with completion 




Such low coverage is likely to hinder achieving the WHO target of reducing TB incidence 
and mortality by 90% by the year 2035.4 
 
IPT uptake has been slow despite it being a priority WHO recommendation for PLHIV for 
over a decade. As of 2019, only 49% of HIV-positive people newly enrolled in ART care 
received IPT globally.8 This study will assess the factors contributing to IPT uptake among 
PLHIV who are enrolled in care at health facilities in Butebo. It is a new district in Eastern 
Uganda that was established in 2017.  Because of this its health system is still developing 
and lacks programmatic indicators to scale up utilization of IPT for TB among its PLHIV. 
This study is relevant due to the very low IPT coverage in Uganda. This indicates that there 
are several barriers to the implementation of IPT policy guidelines. To improve IPT 
coverage and reduce the burden of TB among PLHIV in Butebo district and Uganda at 
large, it is important that the bottlenecks to IPT uptake among eligible PLHIV are identified 
and solved.9 The findings of the study will provide a situational analysis regarding the 
implementation of IPT in Butebo district and serve as an additional knowledge on the 
implementation barriers affecting IPT uptake and completion, as an efficacious tool for TB 







1.2 Conceptual framework  
 
 











The factors that likely influence uptake of IPT amongst PLHIV can be grouped into four 
main categories: 
Demographics of PLHIV 
Factors related to the background of PLHIV include age, gender, marital status, area of 
residence, level of education, employment status, monthly income, and socioeconomic 
status of TB case.4 
 Health facility factors  
They include provider/patient relationship, cost/distance of transportation of PLHIV for 
screening test and collection of isoniazid (INH), screening services, supply of isoniazid, 
the availability and cost per test of tuberculin skin test, chest-X ray (CXR) machine and 
gene X-pert machines. These factors can individually or collectively affect IPT uptake.  
Implementation of IPT by Healthcare providers is influenced by factors like provider 
training on IPT, presence of IPT guidelines, presence of standard operation procedures, as 
well as structural organizational factors which include policy, physical and work 
environment. High-level support and commitment for the IPT program is also necessary 
for to successful IPT implementation.10    
 Community factors  
Fear of acquiring TB, fear of stigmatization, lack of money for transport, level of IPT-
associated health education and adherence to medication in the absence of symptoms by 





 IPT related factors  
These include pill burden, drug side effect, irregular isoniazid supply, isoniazid stock out, 
poor adherence and fear of isoniazid resistance can individually or collectively influence 
adherence and completion.4 
1.3 Study Objectives  
The objectives of this study were to: 
a) Determine the eligible proportion of PLHIV who were initiated on IPT in Butebo. 
b) Identify factors associated with uptake of IPT in Butebo.  
















                                         CHAPTER TWO 
                                                  LITERATURE REVIEW  
2.1 Epidemiology of Tuberculosis 
The estimated global burden of TB in 2018 was 10 million incident cases and TB was a 
leading killer of HIV-positive people. Even though the global incidence of TB is falling at 
about 2% per year, there is need to accelerate to a 4-5% annual decline to reach the 2020 
milestones of the End TB Strategy.12 An estimated 58 million lives were saved through TB 
diagnosis and treatment between 2000 and 201813 and ending the TB epidemic by 2035 is 
among the health targets of the Sustainable Development Goal 3.3.  
TB occurs in every part of the world and poses a great threat to the human lives in Africa 
due to limited and overwhelming health care services.14 The burden of HIV associated TB 
was highest in Africa in 2018 accounting for 24.5% of the new TB cases worldwide. In 
Uganda, the estimated TB incidence rate is 201 per 100,000 persons per year.5  
Globally a total of 748,000 people who were newly enrolled in HIV care were started on 
TB preventive treatment in 2018 representing only 49% of people newly enrolled in HIV 
care. Uganda reported an estimated 34000 PLHIV and having TB in 2018 which accounted 
for 39.4% of all incident TB cases in that yaer.15 However, no data was readily available 
for the proportion of PLHIV who have accessed IPT in Uganda.  
2.2 Etiology and Risk Factors of TB  
TB is almost exclusively transmitted through the inhalation of air droplets containing the 
bacilli from Mycobacterium tuberculosis (Mtb) from patients with active PTB.16 HIV is a 




risk factor for the development of TB. The risk of progression from latent TB to active TB 
is significantly higher among HIV-infected population.17 In 2013, globally PLHIV were 29 
times more likely to develop active TB disease than those who are HIV-negative. Risk 
factors for incident TB amongst HIV patients include being male, having low body mass 
index or middle upper arm circumference, lower CD4 cell count, and advanced WHO 
disease stage.18 In a study done in Tanzania, male gender, WHO clinical stage 3 and 4, 
baseline CD4 count <200 cells/ml and having not used IPT were independently associated 
with the active TB amongst people with HIV and on antiretroviral therapy.19 In Uganda 
where TB is endemic, very few studies have been conducted on the factors of influencing 
uptake of IPT among PLHIV enrolled in care at rural health facility settings.20 
 
2.3 Screening and Detection of TB  
Early detection and diagnosis of TB is essential to the control of the disease.21 Screening 
Pulmonary TB in PLHIV begins with a complete clinical assessment for suggestive signs 
and symptoms such as cough, fever, loss of appetite, weight loss and night sweats, followed 
by the collection of specimens for microbiologic testing. Other available routine 
investigations such as HIV testing, chest radiography, a tuberculin skin test (TST) are 
done.22  
2.4 TB Prevention  
In 2015, WHO adopted the End TB Strategy with the overall goal to “End the global TB 
epidemic” by 2035, and there were three high-level, overarching indicators and related 




the TB incidence rate (new cases per 100,000 population per year); and the percentage of 
TB-affected households that experience catastrophic costs because of TB disease.23 The 
2030 targets are a 90% reduction in TB deaths and an 80% reduction in the TB incidence 
rate, compared with levels in 2015, while the 2035 targets are a 95% reduction in TB deaths 
and a 90% reduction in the TB incidence rate, compared with levels in 2015.7 Essentially, 
the prevention of new infections of Mtb and their progression to TB disease is critical to 
reduce the burden of disease and death caused by TB, and to achieve the End TB Strategy 
targets set for 2030 and 2035.24 Currently, three major categories of health interventions 
are available for TB prevention. These include treatment of latent tuberculosis infection 
(LTBI), prevention of transmission of Mtb through infection prevention and control, and 
vaccination of children with the BCG vaccine.25 
2.5 Isoniazid Prevention Therapy  
IPT is a chemoprophylaxis which reduces the risk of a first episode of TB occurring in 
people exposed to infection or with latent infection and the risk a recurrent episode of TB.26 
WHO recommends Isoniazid taken at a daily dose of 10 mg/kg/day (maximum 300 mg) 
for at least six months. The main groups eligible for preventive therapy are those at most 
risk of progressing to TB disease such as PLHIV, infants and children who are contacts of 
TB patients, as well as people on immune suppressing treatment. To improve on the uptake 
of IPT, the National TB and Leprosy Program in Uganda has guided on enrolment of all 





Figure 2: WHO, 2010. TB Screening and IPT Algorithm for adults and adolescents 










   METHODOLOGY 
3.1 Study design  
This was a retrospective quantitative study to determine the level of IPT uptake, and factors 
contributing to the completion of IPT among eligible PLHIV enrolled in care at the health 
centers in the Financial Year 2019/2020 in Butebo, Uganda. 
3.2 Study area  
The study was conducted in Butebo, a rural district in eastern Uganda with a population of 
about 150,000 people. The district has 13 Health Centers with only 4 of them providing 
comprehensive TB screening, basic diagnostics (sputum smear, Gene Xpert), and treatment 
services. These include: Butebo H/C IV, Kakoro H/C III, Nagwere H/C III and Kabwangasi 
H/C III. They represented entry points for TB/HIV cases where IPT was provided. IPT 
implementation practices in TB treatment health facilities in Butebo are similar and they 
function following the guidelines stipulated by Uganda’s Ministry of Health. Each of the 
TB treatment facilities had two qualified staff working in TB/HIV Clinics. They are 
supposed to be trained in TB management to provide counselling to PLHIV about IPT 
before they start the regimen. INH was provided free of charge to PLHIV in Uganda after 
screening to rule out active TB. All eligible PLHIV were also offered the opportunity to 





3.3 Study population  
PLHIV in Butebo district without active Pulmonary TB and meeting the inclusion criteria 
were studied.  
3.3.1Inclusion criteria  
a) PLHIV and. 
i. Enrolled on ART in the HIV Clinic  
ii. Unlikely to have had active Pulmonary TB 
3.3.2Exclusion criteria  
a) PLHIV and. 
i. Not enrolled on ART at the HIV Clinic  
ii. Diagnosed with active PTB  
3.4 Sampling  
Purposeful sampling was done. Butebo district has 13 health facilities of which only 4 
provided HIV/AIDS and TB Services. These facilities were selected for the study. 
3.6 Quantitative data collection techniques and tools  
Primary data from the IPT, TB, and ART registers or cards for PLHIV were extracted. The 
research assistant filled the questionnaire together with the health worker providing IPT 
care. Lists of relevant questions needed to achieve the study objectives formed the basis 
for the questionnaire.  
3.7 Variables 
The main dependent variable for this study is IPT Uptake. IPT Completion status is a 
consequential dependent variable looked at in this study. Independent variables include 




level, area of residence, household density), health facility factors (pre-IPT counselling), 
community factors (distance from H/C, incurred costs to reach H/C), and IPT drug related 
factors (IPT adherence, default on IPT, frequency of INH refill, INH stockouts) were 
elaborated in the questionnaire. Due to COVID-19 restrictions, only factors obtainable 
















3.8 Definition of variables 
 
Table 1. Variables and their definition as relevant to this study 




Referred to as the years of the 
patient as reported at the time of 
HIV diagnosis and Uptake of IPT. 
Continuous values 
Gender 
Referred to as the sex of the patient 






Referred to whether the patient is 
employed as reported at the time of 





Referred to the marital status 





Referred to the religious 





Referred to as the educational 
status attained by the patient at the 





Referred to the address or area of 




Household density  
Referred to the number of people 
who lived in the same house with 
the patient. 
Continuous values 
Incurred costs to 
reach H/C 
Referred to patient's ability to 
afford money to travel to access 






Distance from H/C 
Referred to as the distance from a 
patient's home to the H/C 
Categorical Values: 5 
km or less/Over 5 km 
Pre-IPT 
counselling 
Referred to whether the patient 
received education talks about IPT 
before starting the treatment  
Categorical values: 
Yes/No 
Default on IPT 
Referred to whether the patient 
dropped out from treatment at a 
point in time. 
Categorical Values: 
Yes/No 
Frequency of INH 
refill 
Referred to regularity of the 




Referred to the stock status of INH 




Referred to whether the patient 





Referred to whether the patient 





Referred to whether the patient 
was committed no to miss some 













3.9 Data Management.  
Questionnaires were attributed to serial numbers that helped match them to the database if 
there was need for cross-verification and the data entered in an electronic data entry form. 
The dataset was stored in personal laptop and backed up. 
3.10 Data analysis  
A preliminary analysis was carried out to make sure that there was no missing data and 
coding was performed to facilitate creation of a data set. SPSS (Statistical Package for the 
Social Science) version 25 was then used to do all the analysis process within this research. 
Association between variables was analyzed by performing Chi-square test between the 
independent variables with the dependent variable. If there was significant association 
between two variables, the analysis was continued with logistic regression analysis.  
3.11 Quality control  
3.11.1 Recruitment and training of research assistants 
To assist in effective data collection, a research assistant from each of the four health 
centers was trained by the Principal Investigator to appreciate the aims and objectives of 
the study, how to collect data as well as ethical considerations of the research.  
3.11.2 Data entry 
Data was checked to ensure that all information was properly identified and filled. Errors 
and omissions detected were discussed and adjusted accordingly.  
 
3.12 Ethical Consideration.  
Ethical clearance for this study was obtained from the Yonsei Severance Hospital 





                RESULTS 
4.0 Recruitment of study samples  
This study was conducted from August 25th to September 15th, 2020. Case files of 272 
patients eligible for this study were obtained and reviewed to obtain data relevant for this 
study. 
4.1 IPT uptake in Butebo district 
 
Table 2. IPT Uptake by Health Center  
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Kakoro 4.63 ± 3.82 7 (13.7) 
17 
(33.3) 
27 (52.9) 51 (100.0) 47.1 
Kabwangas
i 
3.80 ± 3.189 8 (14.5) 
12 
(21.8) 
35 (63.6) 55 (100.0) 36.4 
Nagwere 






29 (56.9) 51 (100.0) 43.1 
Total 










Table 2. above shows the status of IPT uptake for each of the Health Centers. The mean 
duration from HIV diagnosis up to IPT Initiation was 4.31 years with SD of 3.782 years. 




(12.1%) and the highest proportion was Nagwere H/C with 10 (19.6%) while the lowest 
proportion was Butebo H/C having 8 (7%). The general IPT uptake at over 1 year from 
HIV diagnosis was 60 (22.1%) patients and was highest in Kakoro H/C with 17 (33.3%) 
while also lowest in Butebo H/C with 19 (16.5%). The group of No IPT Uptake was the 
majority with 179 (65.8%) patients and the largest number was from Butebo H/C, 88 
(76.5%), and the lowest number from Kakoro H/C, 27 (52.9%). In general, 93 (34.2%) 
patients took up IPT from the 272 who were eligible.  
 
Table 3. IPT Uptake by contributing factors 
         N (%) 
Variable 
IPT UPTAKE STATUS 
Total p-value 
Uptake No Uptake 
Gender 




Male  34 (37.0) 58 (63.0) 
92 
(100.0) 
Age group (Years) 




13 to 19 2 (22.2) 7 (77.8) 9 (100.0) 
20 to 35 28 (41.8) 39 (58.2) 
67 
(100.0) 
36 to 64 53 (32.1) 112 (67.9) 
165 
(100.0) 

















Married 62 (39.5) 95 (60.5) 
157 
(100.0) 














Moslem 18 (30.5) 41 (69.5) 
59 
(100.0) 
Others 0 (0.0) 1 (100.0) 1 (100.0) 
Education level 
Primary 51 (26.2) 144 (73.8) 
195 
(100.0) 
<0.001 Secondary 33 (62.3) 20 (37.7) 
53 
(100.0) 
Tertiary 2 (66.7) 1 (33.3) 3 (100.0) 













2 or less 1 (50.0) 1 (50.0) 2 (100.0) 
0.451 3 to 5 61 (36.7) 105 (63.3) 
166 
(100.0) 
6 or more 31 (29.8) 73 (70.2) 
104 
(100.0) 
Incurred costs to 
reach H/C 













More than 5 


















Table 3 above shows IPT Uptake status in Butebo district by contributing factors. Of the 
272 study cases, 93 (34.2%) were in the category of IPT Uptake while 179 (65.8%) were 
in the category of No IPT Uptake.  
In the Female gender only 59 (32.8%) of them were in the IPT Uptake group while 
among the males only 34 (37.0%) of them were in the IPT Uptake group. The result was 
not statistically significant in this study (p,0.492) hence Gender did not significantly 
affect the IPT Uptake status. 
When age was categorized, only 7 (41.2%) of the cases aged 1-12 years were in the IPT 
Uptake group which was second only to 28 (41.8%) of the 20-35 age group. The least IPT 
Uptake was seen among the cases who were 65 years and over with only 2 (21.4%). The 
result was not statistically significant in this study (p,0.407) hence these age groups did 
not significantly affect the IPT Uptake status.  
 Considering Employment status, 7 (70%) of the Employed cases were in the IPT Uptake 
group compared to 86 (32.8%) of the Unemployed. This result was statistically 
significant in this study (p,0.015) hence employment significantly affected IPT Uptake 
status. 
 Considering Marital status, the highest IPT Uptake was 62 (39.5%) among the Married 
cases while the least uptake was 8 (25.0%) amongst the Divorced cases. The result was 
not statistically significant in this study (p,0.166) hence Marital status did not 




When Religion was considered, 75 (35.4%) of the Christians were in the IPT Uptake 
group which was higher than 18 (30.5%) of the Moslems who took up IPT. The result 
was not statistically significant in this study (p,0.604) hence religion did not significantly 
affect IPT Uptake status. 
When education level was analyzed, IPT Uptake was highest in the category of those 
cases who had Tertiary education 2 (66.7%) while the least uptake was among those who 
only had Primary education 51 (26.2%). The result was highly significant in this study (p, 
<0.001) hence education level very significantly affected IPT Uptake status. 
Considering Residence status, cases from Urban settings 23 (79.3%) were in the IPT 
Uptake group compared to 70 (28.8%) of those from Rural settings. The result was highly 
significant in this study (p, <0.001) hence Residence very significantly affected IPT 
Uptake status. 
When Household density was analyzed, highest IPT Uptake was in group of households 
with 2 or less people, 1 (50%), and the uptake was least in group of households with 6 or 
more people, 31 (29.8%). The result was not statistically significant in this study 
(p,0.451) hence Household density did not significantly affect IPT Uptake status.  
In Costs to reach the H/C category, the highest IPT Uptake was in the group that incurred 
No costs, 43 (45.3%), and lower in the group that Incurred costs to reach the H/C, 50 
(28.2%). The study result was statistically significant for this study (p,0.050) hence 




Distance from the H/C was analyzed and found 63 (35.8%) of those who lived 5 km or 
less from the H/C took up IPT. This was higher than 30 (31.3%) of those who took up 
IPT and stayed more than 5 km from the H/C. This result was not statistically significant 
in this study (p,0.450) hence distance from the H/C did not significantly affect IPT 
Uptake status. 
Pre-IPT counseling factor was analyzed and found that 80 (98.8%) of those who were 
counselled took up IPT. This was higher than 11 (91.9%) who did not receive counselling 
but took up IPT. This result was not statistically significant (p,0.114) hence Pre-IPT 
counselling did not significantly affect IPT Uptake status.  
4.2 IPT Completion in Butebo district 
 
Table 4. IPT Completion by Health Center 
              N (%) 












Butebo 27 (100.0) 0 (0.0) 27 (100.0) 100 
Kakoro 24 (100.0) 0 (0.0) 24 (100.0) 100 
Kabwangasi 18 (90.0) 2 (10.0) 20 (100.0) 90 
Nagwere 22 (100.0) 0 (0.0) 22 (100.0) 100 
Total 91 (97.8) 2 (2.2) 93 (100.0) 97.8 
 
Table 4 above shows the IPT Completion status by Health Center in Butebo district. 91 




treatment compared to 2 (2.2%) who did not complete the treatment. IPT Completion 
was highest in the three Health Centers of Butebo, 27 (100%), Nagwere, 22 (100%), and 
Kakoro, 24 (100%). The lowest IPT Completion was in Kabwangasi H/C, 18 (90%). 
 
Table 5. IPT Completion status by contributing factors 
         N (%) 
Variable 
COMPLETION STATUS 




IPT Adherence Good 84 (100.0) 0 (0.0) 
84 
(100.0) <0.001 
Poor 7 (77.8) 2 (22.2) 9 (100.0) 
Default on IPT 
Yes 4 (66.7) 2 (33.3) 6 (100.0) 
<0.001 
No 87 (100.0) 0 (0.0) 
87 
(100.0) 
Frequency of INH 
refill 
Regular 88 (100.0) 0 (0.0) 
88 
(100.0) <0.001 
Irregular 3 (60.0) 2 (40.0) 5 (100.0) 
INH Stockouts 
Yes 0 (0.0) 1 (100.0) 1 (100.0) 
<0.001 




Table 5 above shows IPT Completion status by contributing factors in Butebo district. 
When IPT Adherence was analyzed, those who had good adherence all completed IPT, 
84 (100%). This was higher than IPT completion among those who had poor adherence, 7 
(77.8%). When IPT default status was analyzed, 4 (66.7%) of those who defaulted from 
treatment were able to complete IPT while majority, 87 (100%), of those who did not 




(100%), of those who had regular refills were able to complete IPT. This was higher than 
only 3 (60%) of those who had Irregular refills but completed IPT. For INH stock status, 
91 (98.9%) of cases experienced no stockouts of INH and completed IPT. All these 
results were highly significant at (p, <0.001) hence the variables very significantly 














CHAPTER FIVE  
            DISCUSSION 
5.1 Discussion 
In this study, 34.2% of the newly diagnosed PLHIV were initiated on IPT. Similar findings 
on IPT uptake were found in epidemiological studies conducted in South India which 
reported 33%28, and in Zambia which reported 30%29. Despite the slight differences in the 
methodology and study designs, the IPT uptake established in this study was found to be 
higher than 6.3%, 18.0%, 22%30, and 26.8%31 which were reported in Malawi32, Timor-
Leste33, India and South Africa respectively. In contrast, other studies in Ethiopia34, 
Gambia35, Rwanda36 and Benin37 reported 64.3%, 89%, 89% and 99% of IPT uptake 
respectively, which were much higher compared to the findings of the current study. The 
integration of IPT into the programmatic delivery of healthcare might explain the high 
uptake reported in the study findings reported in these countries. 
This study results attested that majority of the cases were female although IPT Uptake was 
highest among the males which could be partly explained by the differences in health 
seeking behaviors in the district where more females partake healthcare services than men. 
Majority of cases were unemployed which may be explained by the finding that majority 
of them had attained only primary level of education. Most of the cases initiated on 
treatment lived in rural households within 5 km from the health centers, which could have 
made access to health services more favorable hence influencing uptake of IPT. Majority 
of the cases incurred travel costs probably due to the bad nature of the roads, limited travel 




While majority cases were married, those who lived without partners were also significant 
which could have contributed to poor social support to seek IPT services at the health 
centers. Majority cases were Christians because it is the dominant religion in Butebo 
district.  
The results show that IPT completion rate was high. The factors favorably influencing the 
completion of treatment include good IPT Adherence, limited default on IPT, regular INH 
refills, and No stockouts of INH at the health centers. 
5.2 Study limitations 
The research was conducted in Butebo district; thus, the findings might not be generalized 
to the whole country. A major limitation of this study is the inability to conduct face to face 
interviews with the study cases to determine their personal and community factors that 
determined IPT uptake and completion. This was majorly due to the lockdown regulations 
instituted by the government because of COVID-19 pandemic, and the lack of finances to 
facilitated home visits.  The health workers were also not interviewed to obtain their 







CONCLUSIONS AND RECOMMENDATIONS 
6.1 Conclusions 
This study shows that the recommendations of WHO and Uganda’s National Tuberculosis 
and Leprosy Program (NTLP) for screening all newly diagnosed PLHIV and initiating 
them to IPT were still not well implemented. The rate of IPT uptake was found to be low 
although the completion rate among those who took up treatment was high. Poor IPT 
uptake represents missed opportunities to prevent future Tuberculosis cases amongst the 
PLHIV. The findings in this research are consistent with earlier studies conducted in other 
parts of Africa, and other Low- and Middle-Income Countries (LMICs). Major gaps in IPT 
uptake may be scaled up by addressing the factors affecting IPT Uptake, alongside 
integrating IPT with other routine HIV-AIDS/TB and community care services, enhancing 
supervision and monitoring, training of health workers, and maintaining regular INH 
supplies at the health centers. IPT implementation shortcomings need to be discussed at all 
levels of management from the Health Center to the District level, and centrally at the 









The NTLP and the district(s) should train healthcare providers on the benefits of 
implementing IPT care services, complete data capture and storage, and including IPT 
uptake and completion among the core TB indicators for reporting in the District Health 
Management Information Systems (DHMIS). The health care providers should integrate 
IPT with their routine HIV-AIDS/TB services to capture all potential cases for IPT.   
Community HIV/TB counsellors and VHTs need to be supported further to conduct health 
education and home visits to the PLHIV to increase uptake of IPT and to monitor them 
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